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ABSTRACT
Blood transmitting infectious disease still remains a considerable global health problem. Hepatitis B virus (HBV) and hepatitis C virus 
(HCV) are two of the most commonly transmitted infectious agents. This prospective cross-sectional study was conducted between 
December, 2017, and February, 2018, at the Directorate of Blood Bank in Erbil Province, Northern Iraq. During that period, a total of 
6173 blood donors donated blood; all blood donors were asked a series of questions through a structured questionnaire designed for such 
purpose. These patients were serologically examined for HBV and HCV. Positive blood samples were further analyzed serologically and 
confirmed by real-time polymerase chain reaction (RT-PCR). Among 6173 blood donors who were investigated for HBV, 7 (0.11%) and 
98 (1.6%) were positive for hepatitis B surface antigen (HBs-Ag) and hepatitis B core Antibody (HBc-Ab), respectively, whereas during 
screening for HCV, 4 (0.06%) were positive for HCV-Ab. Coinfection (dual infection (HBV and HCV) was positive in 1 patient (0.01%). 
Among 98 reactive samples, 75.5% were positive for HBs antibody (HBs-Ab), the remaining 24 samples (24.5%) were regarded as occult 
hepatitis B infection (OBI), since they were positive for HBc-Ab, whereas negative both for HBs-Ag and HBs-Ab. The diagnosis of OBI 
could be confirmed by RT-PCR in 8 samples, 33% of samples. The overall incidence of HBV and HCV among examined blood donors 
was 0.5 %, and 0.06%, respectively. Amidst that incidence, 0.39 % were diagnosed as OBI. To prevent viral transmission through blood 
transfusion is needed to combine a different and sensitive method for HBV detection as well as evolve tests that have high sensitivity and 
specificity for serological markers. Moreover, a molecular tool that is sensitive enough to detect very low copies of viral DNA must also 
be developed.
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INTRODUCTION
Infections with hepatitis B virus (HBV) and hepatitis C viruses (HCV) are major global health problems worldwide: It is predictable that about 350 million persons are chronically 
infected with HBV, and nearly 200 million people are infected 
with HCV worldwide. Both hepatitis B and hepatitis C are 
among common infectious liver diseases worldwide.[1] Viral 
hepatitis is a systemic disease primarily affecting the liver, which 
induces acute inflammation of the liver, resulting in a clinical 
illness characterized by fever, gastrointestinal symptoms such 
as nausea, vomiting, and jaundice. Regardless of the virus 
type, identical histopathologic lesions are observed in the 
liver during acute disease.[2] Both HBV and HCV infections 
are known for their parenteral transmission; therefore, blood 
transfusion is a potential route of transmission.[3,4] The risk 
of infection with transfusion-transmitted viruses has been 
reduced remarkably since the introduction of serological 
screening; on the other hand, a zero-risk blood supply remains 
the ideal aim.[5] The risk of transfusion-transmitted HBV 
infection has been reduced by screening all blood donations 
for hepatitis B surface antigen (HBs-Ag) since 1970, screening 
for HBs-Ag is still regarded as an important tool for blood 
screening by the World Health Organization (WHO).[6] It 
was accepted that the disappearance of HBs-Ag indicates 
the clearance of HBV. Meanwhile, many reports pointed to 
the occurrence of post-transfusion hepatitis B despite the 
screening for HBs-Ag, necessitating the use of other markers 
for viral screening. For this, screening for HBc-Ab was 
recommended by the German Advisory Committee Blood in 
March 2005, especially for areas with low HBV prevalence.[7,8] 
Recently in the major blood bank of Erbil, HBc-Ab screening 
has also been performed for all blood donors. The donated 
blood with negative HBs-Ag but positive HBc-Ab will be 
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discarded, these groups of blood donors are either infected 
but have been cured of the diseases, or else the donor is still 
infected with HBV that can be further confirmed and need 
to be further analyzed both serologically and by molecular 
detection using polymerase chain reaction (PCR).[9] The blood 
donors with HBs-Ag negative serology, HBc-Abs positive or 
negative and the presence of viral DNA by PCR are known as 
occult HBV infected occult hepatitis B infection (OBI). OBI 
is a risky group playing an important role in hepatitis virus 
transmission by blood transfusion.[10]
Regarding the HBV prevalence in the world could be 
divided into three areas where the prevalence of chronic HBV 
infection is high (>8%), intermediate (between 2 and 8%), and 
low (<2%).[11] Infection with Hepatitis B and C is regarded as 
a major cause of liver cirrhosis and hepatocellular carcinoma. 
The WHO estimates that 57% of cases of liver cirrhosis and 
78% of primary liver carcinomas result from a hepatitis B or C 
virus.[12] Approximately 70%–80% of HCV-infected patients fail 
to clear the virus and develop chronic HCV infection, which is 
a risk factor for liver diseases such as fibrosis, cirrhosis, and 
hepatocellular carcinoma.[13,14]
Several studies have recorded the prevalence of HBV and 
HCV infection in blood donors of different Iraqi cities.[15-17] 
According to the studies that have been conducted in the past 
years investigating the seroprevalence of hepatitis B and hepatitis 
C, the prevalence rate in our region is low which is <2%.[18,19]
Lack of documentary data in Erbil governments and 
immigration of a significant number of refugees from a 
neighboring country to Kurdistan region, as well as foreign 
tourists and the traveling of Kurdish peoples to other countries, 
necessitate updated research on seroprevalence of infectious 
agents (HBV and HCV) among blood donors. Nonetheless, 
the HBV vaccine was added to the expanded program of 
vaccination in early 2000.[20] There was an absence of data on 
the success of the vaccination program; therefore, we thought 
of evaluating the antibody for these viruses in the blood which 
offer an idea of the level of protection against these infectious 
agents.
This study was conducted to find out the incidence of HBV 
and HCV among blood donors in Erbil community. Besides 
this, we further characterized the HBV infected individuals 
along with the screening for HBs-Ab, evaluating the level of 
protection against HBV infection among our community.
MATERIALS AND METHODS
Study Population and Sampling
This is a prospective and cross-sectional study investigating 
HBV and HCV among blood donors who donated blood in 
the Directorate of Blood Bank-Erbil, Iraq. All volunteers who 
visited the blood bank to donate blood from December 2017 to 
February 2018 were included in the study: Blood donors were 
selected after an interview through a structured questionnaire 
designed for such purpose. Blood donors with low or high 
hemoglobin concentration, high body temperature, having any 
disease, weight <50 kg, cupping in Past 6 months, operation 
in the last year, drinking alcohol, uncontrolled blood pressure, 
history of taking any drugs, fever, and having tattoos on their 
body were excluded in our study.
In total, 6173 participants donated blood during the 
specific time and were screened for HBV and HCV. Among 
those blood donors, 109 were reactive for HBV or HCV. Fifty 
healthy individuals were also included in this study as a control 
group. Each blood sample was collected in a 5 ml of a sterile 
tube, and then the whole blood was centrifuged, plasma was 
taken and stored at minus 20 freezer. The study was approved 
by the Ethics Committee at the Hawler Medical University, for 
dealing with the samples and participant information and a 
written informed consent was obtained from each blood donor 
for their participation in the study.
Detection of HBV Serological Markers
ELISA screening test for HBs Ag and anti-HBc
Monolisa™ HBs Ag ULTRA (Bio-Rad, France) assay is a one-step 
enzyme immunoassay based on the principle of the “sandwich” 
type using monoclonal antibodies and polyclonal antibodies 
selected for their capability to bind themselves to the numerous 
subtypes of HBs Ag.[21] Serologically, the samples were 
rechecked by Elecsys HBs Ag II by device Cobas e411(Roche, 
Germany). The Elecsys HBsAg II assay uses monoclonal and 
polyclonal anti-HBs antibodies (mouse and sheep) for the 
HBsAg determination. Monolisa™ Anti-HBc PLUS (Bio-Rad, 
France) is an enzyme immunoassay (indirect ELISA type) for 
the simultaneous finding of total antibodies to HBV core.[22]
Chemiluminescent immunoassay (CLIA) screening test for 
anti-HBs
CLIA way was used for detecting antibody of HBs by the Liaison 
XL (DiaSorin, Italy). Amid numerous enzyme assays that give 
light-emitting reactions, one of the most successful tests is the 
improved CLIA regarding a horseradish peroxidase labeled 
antibody or antigen and a mixture of the chemiluminescent 
substrate, hydrogen peroxide, and enhancers.[23]
Detection of HCV serological markers
Monolisa™ Anti-HCV PLUS Version 2 or 3 (Bio-Rad, France) is 
an indirect qualitative enzyme immunoassay for the detection 
of infection by the HCV based on the detection of anti-HCV 
antibodies in serum or human plasma.[24]
Detection of HBV DNA (PCR)
The extraction of HBV DNA is done by a kit EZ1 Virus Mini 
kit (v2.0 Qiagen, Germany) using the EZ1 Advanced XL device 
(QIAGEN, Germany).[25] The artus HBV RG PCR Kit is used in the 
automated system for the detection of HBV DNA using the PCR 
on Rotor-Gene Q (QIAGEN, Germany).[26] This is conducted for 
24 samples that are negatives for anti-HBs and positives for anti-
HBc IgG, and six samples are used as a negative control.
Statistical Analysis
Microsoft Office Excel and Statistical Package for the Social 
Sciences (SPSS) are used for data entry and analysis.
RESULTS
Among 6173 participants, 109 were reactive for HBV and HCV. 
Fifty negative samples were also included in this study as a 
control group for further analysis. Among the 159 participants 
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who were included in this study as a test and control group, 
the mean and standard deviation in age for the control group 
was 35.5 ± 8.6 and that for the test group was 40.9 ± 12. 
The ages of blood donors both for test and control group were 
grouped into six groups [Tables 1 and 2]. The minimum age is 
19 years, and the maximum age is 73 years for the test group 
and 22 and 57 years for the control group.
Prevalence of Hepatitis B and Hepatitis C
Serologically, based on detection of HBs-Ag, HBc-Ab, and HCV-Ab, 
we decided whether the patient has HBV or HCV infection. These 
tests were carried out for all the participants (6173). Among all 
examined participants, only 7 patients were reactive for HBs-Ag 
(0.11%), whereas 98 donors were reactive for HBc-Ab (1.58%). 
Regarding HCV infection only 4 patients were positive for anti-
HCV Ab (0.065%), as described in Figures 1 and 2.
Immune Blood Donors for HBV Infection
Among the sero-reactive blood donors for HBV, we further 
characterize them through detection of antibody against 
HBs-Ag (HBs-Ab). Should individuals of HBc-Ab positive blood 
have HBs-Ab in their blood, this indicates that these participants 
are cured of HBV infection and means that they have immunity 
to HBV infection. Among the 98 sero-reactive blood donors, 
74 blood donors were positive for HBs-Ab (75.5 %) indicating 
that they are cured of natural infection.
We also examined 50 healthy volunteers that are free 
from HBV and HCV infection, among them only 4 blood donors 
were positive for HBs-Ab, reflecting the successful vaccination 
and protection against HBV infection [Table 3].
Diagnosing Occult HBV Infection
As we defined OBI before, blood donors with HBs-Ag negative 
serology, HBc-Abs positive or negative, and the presence of viral 
DNA by PCR are known as occult HBV infection (OBI). Blood 
donors with only positive HBc-Ab in the absence of HBs-Ag 
and HBs-Ab are regarded as OBI.[10] In our study, we further 
characterize the positive blood donors. Among the samples 
that are included in our study, 98 samples were positive for 
HBc-Ab, from which 24 blood donors (24.5%) were negative 
for HBs-Ag and HBs-Ab (HBc-Ab +ve, HBs-Ag –ve, and 
HBs-Ab –ve), indicating that these blood donors were defined 
as having occult hepatitis virus infection [Table 3]. These 
24 samples were further investigated for the detection of HBV 
DNA [Figure 3].
HCV Incidence and Dual Infection
In this study, as we mentioned above, besides screening for HBV 
infection, screening for HCV was also done for these participants. 
Among 6173 participants, only four blood donors were positive for 
HCV-Ab 0.06%. Among HCV reactive donors, one individual was 
positive both for HBV infection and HCV infection, which means 
that he has a dual infection [Table 4].
Sero-status in Relation to 
Socio-demographic Characteristics
Among the HBV and HCV positive blood donors, the highest 
frequency of 38 (35%) was found among those aged between 
26 and 35 years (young age groups). Blood donors with 
blood Group O were found to have the highest frequency for 
Table 1: Demographic distribution of the HBV and/or BCV 
positive samples (positive blood donors)
Demographic distribution Frequency (n=%)
Test group
Age groups (year)
Under 25 4 (3.7)
2–35 38 (35)
36–45 33 (30)
46–55 22 (20)
56–65 7 (6.4)
Above 66 5 (4.6)
Blood groups
O 39 (36)
A 36 (33)
B 25 (23)
AB 9 (8)
Occupations
Private sector employee 73 (67)
Public sector employee 30 (27.5)
Unemployed 6 (5.5)
Student -
Total 109 (100)
Table 2: Demographic distribution of the samples control 
group (negative blood donors)
Demographic distribution Frequency (n=%)
Control group
Age groups (year)
Under 25 6 (12)
26–35 25 (50)
36–45 10 (20)
46–55 8 (16)
56–65 1 (2)
Above 66 -
Blood groups
O 17 (34)
A 18 (36)
B 10 (20)
AB 5 (10)
Occupations
Private sector employee 34 (68)
Public sector employee 13 (26)
Unemployed 1 (2)
Student 2 (4)
Total 50 (100)
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its immunoreactivity among test group 39 (36%) [Table 1], 
whereas those with blood Group A are among those with the 
highest frequency among control group 18 (36%) [Table 2]. 
Most of the reactive individuals for HBV positivity were 
among the private sector employees [Table 1]. None of these 
parameters were statistically significant.
Molecular Detection of the HBV by Real-
time Quantitative PCR (RT qPCR)
For further characterization of serum samples from HBs-Ag 
negative, HBs-Ab negative, and HBc-Ab positive blood donors 
were processed for HBV-DNA detection using molecular 
amplification using the RT PCR. This test was done using artus® 
HBV RG* PCR Kit 24, V1 (Qiagen, Germany). After extracting 
the nucleic acid of the HBV by EZ1® Virus Mini Kit v2.0 (Qiagen, 
Germany), we ran the purified DNA of HBV by Rotor-Gene Q 
(Qiagen, Germany). Twenty-four samples were selected (Anti-
HBc IgG positive and negative for anti-HBs), and six control 
samples (negative control) were also included in the study. 
Out of these samples, 8 of the samples (33%) were positive, 
showing the DNA in their blood, confirming the diagnosis of 
occult hepatitis B [Figure 3].
DISCUSSION
Hepatitis B and C viruses are responsible for causing about 80% 
of liver cancer cases worldwide, and it could be the major cause 
of morbidity and mortality.[27] Regarding hepatitis prevalence, 
the world is divided into three areas; low prevalence area, 
which means <2%, an intermediate area 2–8% and high 
prevalence area more than 8%.[28,29] Most countries on the 
earth are still viewed as intermediate to high endemicity for 
HBV infection.[28,29] HCV follows the same division regarding 
prevalence such as low prevalence (<1.5%), moderate 
prevalence (1.5%–3.5%), and high prevalence area, which is 
more than 3.5%.[30]
The current study characterizes and defines the frequency 
of HBV and HCV (6173) blood donors. For HBV detection, 
two serological markers were used (HBs-Ag and Hbc-Ab), 
among those, 98 donors were reactive for HBc-Ab (1.58%), 
whereas only 7 people were positive for HBs-Ag (0.11%). For 
screening of HCV, HCV-Ab was used and only 4 blood donors 
proved positive for anti-HCV-Ab (0.065%), as described in 
Figures 1 and 2.
The prevalence of reactive blood donors in the current 
study for HBV is 1.7% (105 out of 6173) from which 1.5% 
is reactive against HBc-Ab and 0.11% is reactive against 
HBs-Ag, whereas for HCV is 0.06%. They are in agreement 
on a national level with these results by Alhilfi et al., who 
screened 36620 blood donors in Missan Governorate in Iraq, 
Figure 1: Serological and molecular characterization of hepatitis B virus and hepatitis C virus infection among blood donors in the major blood bank of Erbil 
city. HBs Ab – hepatitis B surface antibodies; HBc Ab – hepatitis B core antibodies: PCR – a polymerase chain reaction
Figure 2: Incidence of both hepatitis B virus and hepatitis C virus among 
blood donors
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they found 0.12% positivity for HBs-Ag and 0.09% positivity 
for HCV-Ab.[31] Similar results were also found by Al-Rubaye 
et al., who screened 69915 blood donors in Basra in 2013, 
from which they found 125 reactive individuals for HBs-Ag 
(0.2%), and 1475 reactive individuals for HBc-Ab (2.1%) and 
HCV-Ab positivity in 0.1%.[17]
On an international level, similar results to ours were also 
found in a neighboring country by Boustani et al., which was 
done in Ilam city in Iran between 2009 and 2013: They screened 
72,527 blood donors, they found HBs-Ag in 102 (0.14%), and 
HCV-Ab in 27 (0.037%).[32] Moreover, another study conducted 
in Southwestern Iran, by Sajjadi et al., they Screened 180,304 
blood donors and found HBV in 0.13% and HCV in 0.06%.[33]
On the other hand, our data were much lower than that 
of other related studies performed in other centers. Nationally, 
Hussein et al. performed a study in Duhok at 2004 found HBs-Ag 
in 62/7900 (0.78%), and HCV-Ab in 16/7900 (0.2%).[15]
In addition, internationally, our result was lower than 
those found in India in a study conducted by Gulia, they found 
HBV in 2.54%.[34] In Libya, a study carried out by Qowaider 
et al., they examined 78,987 blood donors in different regions 
in the Northeast in Libya, and they found HBV in 172 blood 
donors (0.21%), and HCV in 197 blood donors (0.24%).[35] 
Furthermore, in Turkey, Hope et al., examined 53,985 blood 
donors, among them 2.1% were positive for HBV and 0.3% 
for HCV.[36]
Besides the blood screening, we further characterized the 
reactive blood donors (positive samples) among 105 positive 
samples for HBc Ab (1.7%), 98 samples were HBc-Ab positive 
but negative for HBs-Ag (HBs-Ag −ve/HBc-Ab +ve), further 
characterization was done for these group by investigating for 
HBs-Ab, among these 74 (75.5%) blood donors were HBs-Ab 
positive (HBc-Ab +ve, HBs-Ag –ve, and HBs Ab +ve) which 
indicated that they are cured of natural infection [Figure 1 and 
Table 3] whereas the remaining 24 blood donors (24.5 %) were 
HBc-Ab positive but negative both for HBs-Ag and HBs-Ab. 
Individuals with negative HBs-Ag and HBs-Ab but positive 
HBc-Ab are defined as occult HBV infection (OBI), this is 
because HBc-Ab is regarded as a pathognomonic marker of HBV 
infection, particularly when HBs-Ag and HBs-Ab are negative.
We performed HBV-DNA detection assay solely on samples 
of blood donors who tested positive for HBc-Ab but negative 
for both HBs-Ag and HBs-Ab (24 samples), including six 
control samples as well. Among 24 samples we could confirm 
the presence of HCV DNA only in 8 (33%) samples, using RT 
PCR, indicating the overall incidence of OBI by DNA detection 
to be about (0.13 %; 8 out of 6173) [Figures 1 and 3]. Based 
on the reaction graph, most of the positive sample has very 
low copy numbers since the reaction was arrived at between 
the 35 and 40 cycles [Figure 3].
Meanwhile, the remaining 16 (66 %) samples were 
HBc-Ab positive but failed to be confirmed by HBV-DNA 
Table 3: Distribution of HBs-Ab among HBc-Ab positive individuals and control group
Serology (HBc IgG) Serology (HBs antibody) P-value
Positive (n=) Negative (n=) Total (n=)
Positive 74 24 98 <0.05
Negative 6 55 61
Total 80 79 159
Hbs Ab: Hepatitis B surface antibodies
Figure 3: Quantitation data for cycling A. Green for hepatitis B virus by real-time quantitative polymerase chain reaction
Table 4: The incidence and percentage of HCV reactive donors 
and dual infection
Serology 
(HBs antigen)
Serology (HCV-Ab)
Positive Negative Total
n= % n=% n=%
Positive 1 (0.6) 7 (4.4) 8 (5.0)
Negative 3 (1.9) 148 (93.1) 151 (95.0)
Total 4 (2.5) 155 (97.5) 159 (100.0)
HCV-Ab: Hepatitis B surface antibodies
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detection. In most of the areas, these groups of blood donors 
are still regarded as OBI, and their blood will be discarded to 
prevent virus transmission.[37]
Internationally, many studies have been published 
throughout the world showing the frequency of OBI within 
HBs-Ag-negative donors, the results are varied: For example 
in the United Kingdom it was 0.56%;[38] in the United State of 
America it was 0.8%;[39] in Iran it was 2.1%;[40] and in Brazil it 
was 3.1%.[41]
On a national level, a similar study performed in Erbil 
City of Iraq shows OBI in 0.09% which is close to our finding 
(0.13%).[42] Discarding the infected blood on the basis of HBc-Ab 
detection, especially in areas where the prevalence of HBc-Ab is 
high (more than 10%), will negatively affect the blood supply. 
In the present study, we found that the incidence of HBc-Ab 
in the Erbil city was low (1.56%, 98 out of 6173) [Figure 1]. 
Further detection of HBs-Ab saved 78 of our samples (75.5%) 
since they were positive for HBs-Ab. On the other hand, DNA 
confirms the OBI only in 8 samples (33%). In high prevalence 
area based on HBc-Ab detection such as Korea, Greece, and 
Ghana, they discarded only blood that is positive for HBV-
DNA, consequently saving more blood units.[43,44] Meanwhile, 
in many places, especially in low prevalence countries, blood 
donor samples were still considered as OBI based on HBC-Ab 
positivity, and all such donated blood was discarded to prevent 
transfusion-transmitted viral infection.
Despite the above, the failure of detecting HBV-DNA 
might be due to a mutation in viral structure, and the false 
serological result might be due to the imperfection of the 
assays used for such purpose.[37]
Many researchers argued in favor of the implementation 
of HBc-Ab or HBV DNA alone or combination for the screening 
of donated blood.[45,46] In a large study screening, 6.5 million 
participants using three markers (HBs-Ag, HBc-Ab, and PCR 
for HBV DNA), prioritizing the use of HBc-Ab along with the 
DNA nucleic acid testing was confirmed for the detection of a 
low level of HBV DNA positive donors.[46]
CONCLUSION
The overall incidences of HBV and HCV among examined 
blood donors were 0.5% and 0.06%, respectively. Among that, 
0.39% were diagnosed as OBI. The highest avoidance of HBV 
blood transmission can be attained by combining a different, 
more sensitive, method for HBV detection with the evolving of 
tests that have high sensitivity and specificity for HBs Ag and 
HBc Ab detection. Further, developing a molecular tool that is 
sensitive enough to detect a very low copy of viral DNA would 
conserve many pints of blood.
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